POLIO
MCID: PLM031
MIFTS: 58

Poliomyelitis (POLIO)

Categories: Infectious diseases, Neuronal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Poliomyelitis

MalaCards integrated aliases for Poliomyelitis:

Name: Poliomyelitis 12 75 53 59 44 15 17 72
Infantile Paralysis 53 72
Polio 53 55

Characteristics:

Orphanet epidemiological data:

59
poliomyelitis
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Childhood; Age of death: any age;

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:4953
ICD9CM 35 045 045.9
MeSH 44 D011051
NCIt 50 C35550
SNOMED-CT 68 54839009
ICD10 33 A80 A80.9
MESH via Orphanet 45 D011051
ICD10 via Orphanet 34 A80.0 A80.1 A80.2 more
UMLS via Orphanet 73 C0032371
Orphanet 59 ORPHA2912
UMLS 72 C0032371 C1527258

Summaries for Poliomyelitis

NIH Rare Diseases : 53 Poliomyelitis is a viral disease that can affect nerves and can lead to partial or full paralysis. It is caused by infection with the poliovirus which can be spread by direct person-to-person contact, by contact with infected mucus or phlegm from the nose or mouth, or by contact with infected feces. There are three basic patterns of polio infection: subclinical infections, nonparalytic, and paralytic. Symptoms vary based on the pattern of infection and can range from asymptomatic with subclinical poliomyelitis to partial or full paralysis. Treatment is aimed at controlling symptoms while the infection runs its course. Since the development of the polio vaccine, the incidence of the disease has been greatly reduced. The prognosis depends on the form of the disease (subclinical, nonparalytic, or paralytic) and the site affected.

MalaCards based summary : Poliomyelitis, also known as infantile paralysis, is related to paralytic poliomyelitis and tetanus. An important gene associated with Poliomyelitis is PVR (PVR Cell Adhesion Molecule), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Neomycin and Polymyxin B have been mentioned in the context of this disorder. Affiliated tissues include testes, spinal cord and brain, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A viral infectious disease that results in destruction located in motor neurons, has material basis in Human poliovirus 1, has material basis in Human poliovirus 2, or has material basis in Human poliovirus 3, which are transmitted by ingestion of food or water contaminated with feces, or transmitted by direct contact with the oral secretions. The infection has symptom fever, has symptom sore throat, has symptom headache, has symptom vomiting, has symptom fatigue, has symptom neck stiffness, has symptom muscle spasms, and has symptom acute flaccid paralysis.

Wikipedia : 75 Polio, short for poliomyelitis, or infantile paralysis, is an infectious disease caused by the... more...

Related Diseases for Poliomyelitis

Diseases related to Poliomyelitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 629)
# Related Disease Score Top Affiliating Genes
1 paralytic poliomyelitis 34.3 PVR ARHGEF1
2 tetanus 31.1 IL4 IL10 IFNG
3 aseptic meningitis 30.9 TNF IL10 IFNG
4 rubella 30.6 TNF IL4 IL10
5 meningitis 30.6 TNF IL10 IFNG FCGR2A
6 neuritis 30.6 TNF IL4 IFNG
7 transient hypogammaglobulinemia 30.5 TNF IL10
8 acquired immunodeficiency syndrome 30.4 TNF IL10 IFNG
9 conjunctivitis 30.3 IL4 IFNG ICAM1
10 herpes zoster 30.2 IL10 IFNG FCGR3A
11 idiopathic achalasia 30.2 TNF IL10
12 penicillin allergy 30.2 IL4 IFNG
13 hepatitis a 30.2 TNF IL10 IFNG
14 osteomyelitis 30.1 TNF IL10 IFNG
15 graft-versus-host disease 30.1 TNF IL10 IFNG
16 sleep apnea 30.1 TNF LEP ICAM1
17 mouth disease 30.1 TNF IL10 IFNG
18 pulmonary edema 30.1 TNF IL10 ICAM1
19 leprosy 3 30.1 TNF IL10 IFNG
20 erythema multiforme 30.0 TNF IFNG ICAM1
21 gastrointestinal system disease 29.9 TNF IL10 IFNG
22 nervous system disease 29.9 TNF IL10 IFNG
23 endocarditis 29.9 TNF IL10 FCGR2A
24 reactive arthritis 29.9 TNF IL10 IFNG
25 immune deficiency disease 29.9 IL4 IL10 BTK
26 bacterial infectious disease 29.9 TNF IL10 IFNG
27 peritonitis 29.8 TNF IL10 ICAM1
28 chagas disease 29.8 TNF IL10 IFNG
29 rheumatic disease 29.7 TNF IL10 IFNG
30 tonsillitis 29.7 TNF IL4 IFNG
31 hemophagocytic lymphohistiocytosis 29.7 TNF IL10 IFNG
32 otitis media 29.7 TNF IL4 IL10
33 gastroenteritis 29.6 TNF IL4 IL10
34 lupus erythematosus 29.6 TNF IL10 FCGR3A FCGR2A
35 allergic hypersensitivity disease 29.6 IL4 IL10 IFNG
36 myasthenia gravis 29.6 TNF IL4 IL10 IFNG
37 behcet syndrome 29.6 TNF IL10 IFNG
38 multiple sclerosis 29.5 TNF IL4 IL10 IFNG ICAM1
39 food allergy 29.4 IL4 IL10 IFNG
40 brucellosis 29.4 TNF IL4 IL10 IFNG
41 mycobacterium tuberculosis 1 29.3 TNF IL4 IL10 IFNG
42 demyelinating disease 29.3 TNF IL10 IFNG ICAM1
43 lichen planus 29.3 TNF IL4 IFNG ICAM1
44 autoimmune disease 29.2 TNF IL4 IL10 IFNG
45 chlamydia 29.1 TNF IL4 IL10 IFNG
46 toxoplasmosis 29.1 TNF IL4 IL10 IFNG
47 schistosomiasis 29.1 TNF IL4 IL10 IFNG
48 bronchiolitis 29.1 TNF IL4 IL10 IFNG
49 viral infectious disease 29.1 TNF IL4 IL10 IFNG
50 allergic rhinitis 29.0 IL4 IL10 IFNG ICAM1

Graphical network of the top 20 diseases related to Poliomyelitis:



Diseases related to Poliomyelitis

Symptoms & Phenotypes for Poliomyelitis

MGI Mouse Phenotypes related to Poliomyelitis:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.24 ARHGEF1 BTK DLG1 FCGR2A FCGR3B ICAM1
2 immune system MP:0005387 10.2 ARHGEF1 BTK DLG1 FCGR2A FCGR3B ICAM1
3 homeostasis/metabolism MP:0005376 10.18 ARHGEF1 BTK DLG1 FCGR3B ICAM1 IFNG
4 digestive/alimentary MP:0005381 10.13 BTK DLG1 ICAM1 IFNG IL10 IL4
5 mortality/aging MP:0010768 10.1 ARHGEF1 BTK DLG1 FCGR2A ICAM1 IFNG
6 endocrine/exocrine gland MP:0005379 10.05 DLG1 ICAM1 IFNG IL10 IL4 LEP
7 integument MP:0010771 9.98 BTK ICAM1 IFNG IL10 IL4 LEP
8 muscle MP:0005369 9.91 ARHGEF1 DLG1 ICAM1 IFNG IL10 LEP
9 neoplasm MP:0002006 9.8 BTK ICAM1 IFNG IL10 LEP TNF
10 no phenotypic analysis MP:0003012 9.73 DLG1 FCGR3B IFNG IL10 IL4 TNF
11 respiratory system MP:0005388 9.63 DLG1 IFNG IL10 IL4 LEP TNF
12 skeleton MP:0005390 9.56 DLG1 FCGR2A FCGR3B IFNG IL10 IL4
13 vision/eye MP:0005391 9.17 DLG1 ICAM1 IFNG IL10 IL4 LEP

Drugs & Therapeutics for Poliomyelitis

Drugs for Poliomyelitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 150)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
2
Polymyxin B Approved, Vet_approved Phase 4 1404-26-8
3
Zinc Approved, Investigational Phase 4 7440-66-6 32051
4
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
5
Calcium carbonate Approved, Investigational Phase 4 471-34-1
6
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
7
Pentetic acid Approved Phase 4 67-43-6
8
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049
9
Inulin Approved, Investigational, Nutraceutical Phase 4 9005-80-5 24763
10
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
11
BCG vaccine Investigational Phase 4
12 Antibodies, Blocking Phase 4
13 Polymyxins Phase 4
14 Antioxidants Phase 4
15 Acidophilus Phase 4
16 Micronutrients Phase 4
17 Nutrients Phase 4
18 Trace Elements Phase 4
19 Zinc Supplement Phase 4
20 Fibrinolytic Agents Phase 4
21 Anticoagulants Phase 4
22 Hormones Phase 4
23 Hormone Antagonists Phase 4
24 Adrenocorticotropic Hormone Phase 4
25 Melanocyte-Stimulating Hormones Phase 4
26 beta-endorphin Phase 4
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
28 Immunoglobulin A Phase 4
29 retinol Phase 4
30 Vitamins Phase 4
31 Retinol palmitate Phase 4
32 Protective Agents Phase 4
33 Antidotes Phase 4
34 Chelating Agents Phase 4
35 Iron Chelating Agents Phase 4
36 Vaccines Phase 4
37 Immunologic Factors Phase 4
38 Antibodies Phase 4
39 Immunoglobulins Phase 4
40 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
41 Chrysanthemum Phase 4
42
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
43
leucovorin Approved Phase 3 58-05-9 143 6006
44
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
45
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
46
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
47
Irinotecan Approved, Investigational Phase 3 100286-90-6, 97682-44-5 60838
48
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
49
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
50
Etoposide Approved Phase 3 33419-42-0 36462

Interventional clinical trials:

(show top 50) (show all 325)
# Name Status NCT ID Phase Drugs
1 A Phase 4, Randomized, Open-Label Study to Assess Humoral and Intestinal Polio Immunity Following a Three-Dose Trivalent Inactivated Polio Vaccine Schedule Relative to Two Sequential Schedules of IPV/Bivalent Oral Polio Vaccines Unknown status NCT01841671 Phase 4
2 Safety Study of IMOVAX Polio™ in Selected Cities in China, an Observational Post Marketing Study Completed NCT01244464 Phase 4
3 Evaluation of GSK Biologicals' Boostrix™ Polio in Healthy Adults, 10 Years After a Booster Vaccination Completed NCT01323959 Phase 4
4 Large Scale Safety Study of IMOVAX Polio in Selected Cities in China, an Observational Post Marketing Study Completed NCT01278433 Phase 4
5 Immunogenicity and Safety of Different Sequential Schedules of Inactivated Poliomyelitis Vaccine (IMOVAX Polio®) Followed by Oral Poliomyelitis Vaccine in Healthy Infants in China Versus Oral Poliomyelitis Vaccine Alone. Completed NCT01475539 Phase 4
6 Immunogenicity and Safety of IMOVAX POLIO® Subcutaneous as a Booster Given in Pre-school Age Children in Japan Completed NCT02005536 Phase 4
7 Antibody Persistence in 11 to 13-year-old Children Previously Vaccinated at 6 Years Old With Either REVAXIS or DT Polio, and Immune Response to a Booster Dose of TETRAVAC-ACELLULAIRE Completed NCT01546909 Phase 4
8 A Phase 4 Study to Evaluate the Safety and Immunogenicity of Monovalent Oral Polio Vaccine Type 2 in Healthy IPV-vaccinated Children Aged 1 to 5 Years in Lithuania Completed NCT02582255 Phase 4
9 A Phase 4 Study to Evaluate the Safety and Immunogenicity of Trivalent Oral Polio Vaccine in Healthy Polio Vaccinated Children 1 to 5 Years of Age and in Healthy Unvaccinated Infants at 6 Weeks of Age in the Dominican Republic Completed NCT02580201 Phase 4
10 Open Clinical Study to Assess the Immune Response and Safety of a Booster Dose (5th Dose) of a Combination Vaccine Against Diphteria-Tetanus-Pertussis-Polio Given to Healthy Adolescents 15-16 Years of Age. Completed NCT00514059 Phase 4 Boostrix polio
11 Assessing Immunogenicity of Type 2 Monovalent Oral Poliovirus Vaccine Administered at One, Two or Four Week Intervals and When Coadministered With Inactivated Poliovirus Vaccine in an Urban Area in Bangladesh Completed NCT02643368 Phase 4
12 Polio End-game Strategies - Poliovirus Type 2 Challenge Study Completed NCT02189811 Phase 4
13 A Phase 4, Randomized Study to Evaluate the Safety and the Humoral and Intestinal Immunogenicity of One or Two Additional Doses of Licensed Inactivated Polio Vaccines (IPVs) in Latin American Infants Previously Vaccinated With Bivalent Oral Polio Vaccines (bOPVs) Completed NCT01831050 Phase 4
14 A Phase 4, Randomized Trial to Assess the Safety and Immunogenicity of Inactivated Poliovirus Vaccine When Given Concomitantly With Measles and Rubella Combined Vaccine and Yellow Fever Vaccine at Nine Months and When Administered Via Different Vaccination Routes Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
15 Supplementation With Zinc and/or Probiotics to Enhance the Immune Response of Oral Rotavirus and Polio Vaccines in Indian Infants Completed NCT01616693 Phase 4
16 Immunogenicity of Combined Bivalent OPV and IPV Vaccines at 9 - 12 Months of Age Compared to bOPV Alone in Malnourished and Non-Malnourished Pakistani Infants. Completed NCT01695798 Phase 4
17 Assessing the Intestinal and Humoral Immunity of Sequential Schedules of Inactivated Poliovirus Vaccine and Bivalent Oral Poliovirus Vaccine for Routine Childhood Immunization in Bangladesh Completed NCT02412514 Phase 4
18 Immunogenicity and Safety of the Sanofi Pasteur's DTacP-IPV Combined Vaccine (TETRAXIM™) Given as a Booster Dose at 4 to 6 Years of Life in Children Previously Vaccinated With PENTAXIM™ in the Study E2I34 Completed NCT01031303 Phase 4
19 A Phase 4 Study to Evaluate the Safety and Immunogenicity of Monovalent Oral Polio Vaccine Type 2 in Healthy Children Aged 1 to 5 Years and in bOPV-IPV Vaccinated Healthy Infants Completed NCT02521974 Phase 4
20 Immunogenicity and Safety Study of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated Polio-virus and Haemophilus Influenzae Type b Vaccine (Infanrix Hexa™) (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02422264 Phase 4 Prevnar13
21 A Randomised Controlled Trial Comparing Two-Dose Priming With the 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks to 6 and 14 Weeks in Nepali Children Completed NCT02385513 Phase 4
22 Evaluation of GSK Biological's dTpa-IPV Booster Vaccine in Children and Adolescents, 5 Years After Previous dTpa-IPV Boosting. Completed NCT00635128 Phase 4
23 A Phase IV (Not Interventional), Open-label, Multicentre Study to Evaluate the Reactogenicity and Safety of Co-administration of GlaxoSmithKline Biologicals' DTPa (Infanrix) and IPV (Poliorix) Vaccines Administered as Three-dose Primary Immunisation Course at 3, 4.5 and 6 Months of Age in Healthy Children in Russian Federation Completed NCT01094171 Phase 4
24 Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants Completed NCT03147560 Phase 4
25 Immunogenicity of a Booster Dose of Fractional Inactivated Poliovirus Vaccine (fIPV) Delivered Intradermally Concomitantly With Rotavirus Vaccines Completed NCT02847026 Phase 4
26 Regulatory Post-Marketing Surveillance (PMS) Study for TETRAXIM™(Combined Vaccine of Adsorbed Diphtheria, Tetanus, Acellular Pertussis and Enhanced Inactivated Poliomyelitis) Completed NCT01437423 Phase 4
27 Immunogenicity and Reactogenicity Study of a New Formulation of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children Completed NCT00611559 Phase 4
28 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
29 The Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR) Completed NCT01129284 Phase 4 ACTHAR gel
30 Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Infanrix Hexa™ (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02853929 Phase 4
31 Reactogenicity of Acellular Pertussis Vaccine Booster in Adolescents Who Have Received 5 Prior Doses of BIKEN Acellular Pertussis Vaccine in Combination With Diphtheria and Tetanus Toxoids (TRIPEDIA®) or Who Have Received Primary Vaccination With 3 Doses of Whole-Cell Pertussis Vaccine, Plus at Least 1 Pertussis Booster Vaccination Completed NCT00304265 Phase 4
32 Randomised Study of the Impact of Different Doses of Vitamin A on Childhood Morbidity and Mortality Completed NCT00168584 Phase 4 Vitamin A
33 Study to Assess and Compare the Immunogenicity and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA) and Aventis Pasteur MSD's DTPa-HBV-IPV-Hib Vaccine (HEXAVAC™) Given at 3, 5 and 11-12 Months of Age Completed NCT01457547 Phase 4
34 Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Infanrix Hexa Vaccine in Healthy Infants Completed NCT00753649 Phase 4
35 Antibody Persistence in Children Previously Vaccinated With Three Doses of Infanrix Hexa™ or Infanrix-IPV/Hib™ Completed NCT01358825 Phase 4
36 Assessment of the Immunogenicity of Three Doses of Bivalent, Trivalent or Type One Monovalent Oral Poliovirus Vaccines Provided at 2 or 4 Week Intervals Completed NCT01633216 Phase 4
37 An Open, Multicentric, Post-marketing Surveillance Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 and 18 Months of Age, in Healthy Infants. Completed NCT00325156 Phase 4
38 Immunogenicity and Safety Profile of Primary Dose of Bivalent OPV (bOPV Bio Farma) Given Simultaneously With Pentabio® And Inactivated Poliovirus Vaccine (IPV) at the 4th Visit in Indonesian Infants Completed NCT03310073 Phase 4
39 Post-marketing, Randomized, Open-label Study to Assess the Immunogenicity and Safety of Concomitant Administration of V260 and Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Japanese Healthy Infants Completed NCT01926015 Phase 4
40 A Randomized, Multi-center, Controlled Clinical Trial for Evaluating the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPV Completed NCT04054492 Phase 4
41 Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Completed NCT00254917 Phase 4
42 Safety of the DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM®) Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China Completed NCT01491087 Phase 4
43 A Randomised Controlled Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants Completed NCT02145624 Phase 4 Repevax;Boostrix-IPV
44 An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age. Completed NCT01659996 Phase 4
45 A Phase IV, Randomized Study to Evaluate the Immune Response of UK Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life Completed NCT00625677 Phase 4
46 Trial of Two-Dose Standard Measles Vaccination Schedule: Long-Term Impact on Morbidity and Mortality of a Two-Dose Vaccination Schedule at 6 and 9 Months of Age Compared With a Standard Regimen of One Dose at 9 Months of Age Completed NCT00168662 Phase 4
47 Assessment of the Effectiveness of Seasonal Trivalent Influenza Vaccine Among Children in Senegal Completed NCT00893906 Phase 4
48 Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study Completed NCT02542462 Phase 4 Rotarix®,;Rotarix®, with other routine vaccines;RotaTeq®,;RotaTeq®, with other routine vaccines
49 Non-specific Effects of Vaccines - In Search of the Immunological Background Completed NCT00168545 Phase 4
50 A Phase IV Study to Evaluate the Primary and Booster Immune Responses of UK Infants Receiving a Licensed 6-in-1 DTaP/IPV/Hib/HBV Vaccine (Infanrix-HexaTM) With a 13-valent Pneumococcal Conjugate Vaccine and Incorporating a Randomisation Study of a Single Dose of 3 Different Meningococcal Group C Conjugate Vaccines at 3 Months of Age Completed NCT01896596 Phase 4

Search NIH Clinical Center for Poliomyelitis

Cochrane evidence based reviews: poliomyelitis

Genetic Tests for Poliomyelitis

Anatomical Context for Poliomyelitis

MalaCards organs/tissues related to Poliomyelitis:

41
Testes, Spinal Cord, Brain, Bone, Kidney, Lung, Breast

Publications for Poliomyelitis

Articles related to Poliomyelitis:

(show top 50) (show all 20021)
# Title Authors PMID Year
1
Stable isotope labeling by amino acids in cell culture and differential plasma membrane proteome quantitation identify new substrates for the MARCH9 transmembrane E3 ligase. 9 38
19457934 2009
2
Novel BTK mutation presenting with vaccine-associated paralytic poliomyelitis. 9 38
18317803 2008
3
Evidence for emergence of diverse polioviruses from C-cluster coxsackie A viruses and implications for global poliovirus eradication. 9 38
17517601 2007
4
Feasibility study to develop a common in vitro D antigen assay for inactivated poliomyelitis vaccines. 9 38
16336935 2005
5
A poliomyelitis model through mucosal infection in transgenic mice bearing human poliovirus receptor, TgPVR21. 9 38
15033568 2004
6
Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impact. 9 38
14654644 2003
7
Tissue-specific replicating capacity of a chimeric poliovirus that carries the internal ribosome entry site of hepatitis C virus in a new mouse model transgenic for the human poliovirus receptor. 9 38
12970433 2003
8
Establishment of European Pharmacopoeia BRP batch 2 for inactivated poliomyelitis vaccine for in vitro D antigen assay. 9 38
14563307 2003
9
The neuropathology observed in wild-type mice inoculated with human poliovirus mirrors human paralytic poliomyelitis. 9 38
12220986 2002
10
Recent insights into poliovirus pathogenesis. 9 38
11597452 2001
11
Identification of a nuclear respiratory factor-1 binding site within the core promoter of the human polio virus receptor/CD155 gene. 9 38
10777530 2000
12
Expression of the poliovirus receptor in intestinal epithelial cells is not sufficient to permit poliovirus replication in the mouse gut. 9 38
9188553 1997
13
Inactivated poliovirus vaccine protects transgenic poliovirus receptor mice against type 3 poliovirus challenge. 9 38
9203668 1997
14
Identification of two determinants that attenuate vaccine-related type 2 poliovirus. 9 38
1847458 1991
15
Prior poliomyelitis-reduced capillary supply and metabolic enzyme content in hypertrophic slow-twitch (type I) muscle fibres. 9 38
2030351 1991
16
Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. 9 38
2170026 1990
17
Identification of genes and pathways in human antigen-presenting cell subsets in response to polio vaccine by bioinformatical analysis. 38
31187886 2019
18
Acute flaccid myelitis and enterovirus D68: lessons from the past and present. 38
31338675 2019
19
Association of Enterovirus D68 with Acute Flaccid Myelitis, Philadelphia, Pennsylvania, USA, 2009-2018. 38
31407660 2019
20
Quality of life assessment scales in polio survivors: a scoping review. 38
31028511 2019
21
Estimating the effect of measles vaccination on child growth using 191 DHS from 65 low- and middle-income countries. 38
31300290 2019
22
Enteroviral meningitis reduces CSF concentration of Aβ42, but does not affect markers of parenchymal damage. 38
31093802 2019
23
2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. 38
31413005 2019
24
Acute flaccid myelitis-Clustering of polio-like illness in the tertiary care centre in Southern India. 38
30169722 2019
25
Contemporary Circulating Enterovirus D68 Strains Infect and Undergo Retrograde Axonal Transport in Spinal Motor Neurons Independent of Sialic Acid. 38
31167912 2019
26
Polio-Like Manifestation of Powassan Virus Infection with Anterior Horn Cell Involvement, Canada. 38
31158072 2019
27
Evaluation of antigenic differences between wild and Sabin vaccine strains of poliovirus using the pseudovirus neutralization test. 38
31427704 2019
28
Growing up with a disability following paralytic poliomyelitis: experiences from persons with late effects of polio. 38
31382857 2019
29
Vaccination Status in Pediatric Solid-Organ Transplant Recipients and Their Household Members. 38
31050613 2019
30
Enterovirus A71 neurologic complications and long-term sequelae. 38
31395054 2019
31
Identification of plasticity and interactions of a highly conserved motif within a picornavirus capsid precursor required for virus infectivity. 38
31409836 2019
32
Immunisation of migrants in EU/EEA countries: Policies and practices. 38
31296374 2019
33
Trends in governmental expenditure on vaccination programmes in the Netherlands, a historical analysis. 38
31420172 2019
34
Integration of hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine within existing national recommendations following a birth dose of monovalent hepatitis B virus vaccine: results of a systematic review in the Asia Pacific region. 38
31328999 2019
35
Poliomyelitis outbreak in Papua New Guinea: health system and health security implications for PNG and Australia. 38
31318056 2019
36
Do mobile phone-based reminders and conditional financial transfers improve the timeliness of childhood vaccinations in Tanzania? Study protocol for a quasi-randomized controlled trial. 38
31272487 2019
37
Social mobilization for cholera prevention & control in India: Building on the existing framework. 38
31331775 2019
38
Coverage and factors associated with full immunisation among children aged 12-59 months in Bangladesh: insights from the nationwide cross-sectional demographic and health survey. 38
31289076 2019
39
Intraoperative customization of intramedullary nails - First results. 38
31378545 2019
40
Paediatric immunisation and chemoprophylaxis in a Ugandan sickle cell disease clinic. 38
30411430 2019
41
Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV). 38
31248293 2019
42
Vaccination uptake and income inequalities within a mass vaccination campaign. 38
31307532 2019
43
Two centuries of immunisation in the UK (part II). 38
31302603 2019
44
Movement Analysis in Orthopedics and Trauma Surgery - Measurement Systems and Clinical Applications. 38
31291674 2019
45
The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. 38
31174831 2019
46
Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: a systematic review and network meta-analysis. 38
31350192 2019
47
Progress Toward Poliomyelitis Eradication - Nigeria, January 2018-May 2019. 38
31344023 2019
48
Immunogenicity of a combined schedule of trivalent oral and inactivated polio vaccines in South African infants. 38
31194605 2019
49
Goodbye to Polio. 38
31334827 2019
50
Polio eradication campaign loses ground. 38
31296745 2019

Variations for Poliomyelitis

Expression for Poliomyelitis

Search GEO for disease gene expression data for Poliomyelitis.

Pathways for Poliomyelitis

Pathways related to Poliomyelitis according to GeneCards Suite gene sharing:

(show all 48)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 TNF PVR IL4 IL10 IFNG ICAM1
2
Show member pathways
13.43 TNF IL4 IL10 IFNG ICAM1 BTK
3
Show member pathways
12.79 TNF IL4 IL10 IFNG ICAM1
4
Show member pathways
12.55 TNF IL4 IL10 IFNG BTK
5
Show member pathways
12.51 TNF IL4 IL10 IFNG
6
Show member pathways
12.5 TNF IL4 IL10 IFNG DLG1
7 12.5 TNF PVR IL4 IL10 IFNG BTK
8
Show member pathways
12.45 TNF IL4 IFNG ICAM1 FCGR3B FCGR3A
9
Show member pathways
12.33 LEP IL4 IL10 IFNG
10
Show member pathways
12.26 TNF IL4 IFNG ICAM1
11
Show member pathways
12.18 TNF IL4 IL10 IFNG
12 12.13 TNF IL10 IFNG FCGR3B FCGR3A FCGR2A
13
Show member pathways
12.09 TNF IL4 IFNG
14 12.05 FCGR3B FCGR3A FCGR2A
15 12.01 TNF IFNG ICAM1
16 12 PVR ICAM1 FCGR3A
17
Show member pathways
12 IL4 IL10 IFNG ICAM1 BTK
18
Show member pathways
11.98 TNF IL10 IFNG
19
Show member pathways
11.97 FCGR3B FCGR2A BTK
20 11.95 FCGR2A BTK ARHGEF1
21 11.93 TNF IL4 IL10 ICAM1
22 11.92 TNF IL4 IL10 IFNG FCGR2A
23 11.91 TNF IFNG FCGR3B FCGR3A FCGR2A BTK
24 11.85 TNF IL10 IFNG
25 11.85 TNF ICAM1 BTK
26
Show member pathways
11.83 TNF IL4 IFNG FCGR3B FCGR3A FCGR2A
27 11.81 TNF IFNG ICAM1
28
Show member pathways
11.77 TNF IL4 IL10 IFNG FCGR3B FCGR3A
29 11.75 TNF IL4 IL10 IFNG
30 11.75 IL10 ICAM1 FCGR3B FCGR3A FCGR2A
31 11.74 IL4 IFNG ICAM1
32 11.71 TNF LEP IL4 IFNG ICAM1 FCGR2A
33
Show member pathways
11.7 TNF IL4 IFNG
34 11.68 TNF IL10 IFNG
35
Show member pathways
11.6 TNF IFNG ICAM1
36 11.53 TNF IL10 IFNG ICAM1
37 11.52 TNF IL4 IL10 ICAM1
38 11.45 IL4 IL10 IFNG
39 11.35 TNF IL10 IFNG ICAM1
40 11.27 TNF IL4 IFNG
41 11.2 TNF IL4 IL10 IFNG
42 11.17 IL4 IL10 IFNG
43 11.15 TNF IL4 IL10 BTK
44 11.1 IFNG ICAM1
45 11.04 TNF LEP
46 11.02 TNF IL4 IL10 IFNG FCGR3B FCGR3A
47 10.93 TNF IL4 IL10 BTK ARHGEF1
48 10.89 TNF ICAM1

GO Terms for Poliomyelitis

Cellular components related to Poliomyelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 TNF PVR LEP IL4 IL10 IFNG
2 extracellular space GO:0005615 9.5 TNF PVR LEP IL4 IL10 IFNG
3 membrane raft GO:0045121 8.92 TNF ICAM1 DLG1 BTK

Biological processes related to Poliomyelitis according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.89 TNF IL4 IL10 ICAM1
2 cellular response to lipopolysaccharide GO:0071222 9.83 TNF IL10 ICAM1
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.82 TNF ICAM1 BTK
4 regulation of immune response GO:0050776 9.8 PVR IL4 ICAM1 FCGR3A
5 response to organic substance GO:0010033 9.77 TNF IL10 BTK
6 response to insulin GO:0032868 9.74 LEP IL10 ICAM1
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 LEP IL4 IFNG
8 regulation of insulin secretion GO:0050796 9.71 TNF LEP IFNG
9 positive regulation of protein complex assembly GO:0031334 9.65 TNF IFNG
10 cortical actin cytoskeleton organization GO:0030866 9.65 TNF DLG1
11 positive regulation of protein localization to plasma membrane GO:1903078 9.65 TNF IFNG DLG1
12 positive regulation of osteoclast differentiation GO:0045672 9.64 TNF IFNG
13 leukocyte tethering or rolling GO:0050901 9.63 TNF LEP
14 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.63 TNF IFNG
15 negative regulation of B cell proliferation GO:0030889 9.62 IL10 BTK
16 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.62 TNF IL10
17 negative regulation of growth of symbiont in host GO:0044130 9.61 TNF IL10
18 negative regulation of glucose import GO:0046325 9.61 TNF LEP
19 negative regulation of lipid storage GO:0010888 9.58 TNF LEP
20 endothelial cell apoptotic process GO:0072577 9.58 TNF IL10
21 positive regulation of nitric oxide biosynthetic process GO:0045429 9.58 TNF IFNG ICAM1
22 positive regulation of MHC class II biosynthetic process GO:0045348 9.55 IL4 IL10
23 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.52 TNF ICAM1
24 negative regulation of cytokine secretion involved in immune response GO:0002740 9.51 TNF IL10
25 type 2 immune response GO:0042092 9.46 IL4 IL10
26 regulation of isotype switching GO:0045191 9.43 IL4 IL10
27 negative regulation of endothelial cell apoptotic process GO:2000352 9.43 IL4 IL10 ICAM1
28 receptor biosynthetic process GO:0032800 9.37 TNF IL10
29 negative regulation of mitotic cell cycle GO:0045930 9.33 TNF IL10 DLG1
30 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.32 TNF IFNG
31 immune response GO:0006955 9.1 TNF IL4 IL10 IFNG FCGR3B FCGR3A
32 positive regulation of vitamin D biosynthetic process GO:0060557 8.96 TNF IFNG

Molecular functions related to Poliomyelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 TNF IL4 IL10 IFNG
2 IgG binding GO:0019864 8.8 FCGR3B FCGR3A FCGR2A

Sources for Poliomyelitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....